- Home
- REBN vs LPCN Comparison
REBN vs LPCN Comparison
Compare REBN & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- LPCN
- Stock Information
- Founded
- REBN 2015
- LPCN 1997
- Country
- REBN United States
- LPCN United States
- Employees
- REBN N/A
- LPCN N/A
- Industry
- REBN Restaurants
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- REBN Consumer Discretionary
- LPCN Health Care
- Exchange
- REBN Nasdaq
- LPCN Nasdaq
- Market Cap
- REBN 15.3M
- LPCN 16.1M
- IPO Year
- REBN 2022
- LPCN N/A
- Fundamental
- Price
- REBN $2.52
- LPCN $2.88
- Analyst Decision
- REBN
- LPCN Strong Buy
- Analyst Count
- REBN 0
- LPCN 2
- Target Price
- REBN N/A
- LPCN $9.00
- AVG Volume (30 Days)
- REBN 89.9K
- LPCN 16.6K
- Earning Date
- REBN 08-14-2025
- LPCN 11-06-2025
- Dividend Yield
- REBN N/A
- LPCN N/A
- EPS Growth
- REBN N/A
- LPCN N/A
- EPS
- REBN N/A
- LPCN N/A
- Revenue
- REBN $6,565,623.00
- LPCN $4,208,119.00
- Revenue This Year
- REBN $335.98
- LPCN N/A
- Revenue Next Year
- REBN N/A
- LPCN N/A
- P/E Ratio
- REBN N/A
- LPCN N/A
- Revenue Growth
- REBN 14.03
- LPCN N/A
- 52 Week Low
- REBN $1.03
- LPCN $2.68
- 52 Week High
- REBN $8.30
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- REBN 44.40
- LPCN 42.44
- Support Level
- REBN $2.33
- LPCN $2.85
- Resistance Level
- REBN $2.89
- LPCN $3.08
- Average True Range (ATR)
- REBN 0.18
- LPCN 0.10
- MACD
- REBN 0.01
- LPCN 0.00
- Stochastic Oscillator
- REBN 36.25
- LPCN 12.82
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.